Overview
Desquamative gingivitis (DG) is a chronic inflammatory condition characterized by the abnormal shedding of epithelial cells in the gingival tissues. This condition predominantly affects individuals over the age of 30, with a notable female predominance, particularly in those experiencing hormonal fluctuations such as menopause. The clinical presentation often includes desquamation, erythema, vesicular formations, and atrophy, leading to significant discomfort and functional impairment. Understanding the pathophysiology, epidemiology, and clinical features of DG is crucial for timely diagnosis and effective management. The condition can be challenging to diagnose due to its varied presentation and potential overlap with other mucosal disorders, necessitating a comprehensive approach that includes clinical examination, histopathological assessment, and targeted laboratory investigations.
Pathophysiology
The pathophysiology of desquamative gingivitis (DG) involves complex interactions between microbial factors, immune responses, and potential hormonal influences. Studies have highlighted a significant association between elevated levels of Eikenella corrodens in subgingival plaque and the development of DG, with these levels being up to 13-fold higher compared to patients with plaque-induced gingivitis [PMID:28304209]. This bacterium's prominence suggests a possible role in triggering or exacerbating the inflammatory cascade characteristic of DG. The chronic inflammation leads to the characteristic desquamation of the gingival epithelium, manifesting as erosions, atrophy, and diffuse erythema. Additionally, hormonal influences, particularly in women, may contribute to the condition's prevalence and severity. Hormonal changes, such as those occurring during menopause, have been implicated in exacerbating symptoms, indicating a potential interplay between hormonal status and immune modulation in DG [PMID:38749724]. These findings underscore the importance of considering both microbiological and hormonal factors in understanding the underlying mechanisms of DG.
Epidemiology
Desquamative gingivitis (DG) predominantly affects individuals over 30 years of age, with a notable gender bias favoring females [PMID:38749724]. Studies have shown that women, especially those experiencing hormonal fluctuations such as menopause, exhibit a higher prevalence of DG, suggesting a possible hormonal influence on the condition's manifestation [PMID:38749724]. A study involving 29 females and 12 males highlighted this gender distribution bias, indicating that females may be more susceptible to DG [PMID:32651518]. The delay in seeking diagnosis is another critical aspect, with patients often waiting an average of 10.8 ± 10 months before consulting a professional, followed by an additional average delay of 7.3 ± 5 months across multiple healthcare consultations before a definitive diagnosis is made [PMID:32651518]. This prolonged diagnostic delay can be attributed to less severe disease severity and female gender, emphasizing the need for heightened clinical awareness and patient education to facilitate earlier intervention.
Clinical Presentation
Desquamative gingivitis (DG) presents with a constellation of clinical features that primarily affect the gingival tissues. Characteristic manifestations include chronic loss of epithelial elements, leading to desquamation, vesicular formations, atrophy, and erosion, often accompanied by diffuse erythema of the marginal and keratinized gingivae [PMID:2]. Symptoms can range from mild discomfort to severe pain, particularly exacerbated by acidic foods [PMID:1]. The research underscores typical clinical presentations such as desquamative erosion, edematous erythema, and vesicle formation, with significant gingival pain being a common complaint [PMID:38749724]. Lesions are frequently observed in the maxillary region, with 60% primarily affecting the anterior gingiva and 40% in the posterior regions [PMID:26312984]. Patient response to treatment can vary widely; for instance, while 17 patients showed improvement with clobetasol propionate, five experienced worsening symptoms, highlighting the variability in individual outcomes [PMID:19784470]. These clinical observations underscore the importance of a tailored approach to managing DG, considering both the severity and individual patient response.
Diagnosis
Accurate diagnosis of desquamative gingivitis (DG) requires a multifaceted approach encompassing clinical examination, histopathological assessment, and laboratory investigations to rule out systemic conditions and differentiate from other mucosal disorders. Histopathological examination often reveals characteristic features such as acanthosis, parakeratosis, and a mixed inflammatory infiltrate, supporting the diagnosis [PMID:4]. Recent studies suggest that urinary equol testing may offer a novel diagnostic avenue, potentially identifying patients who could benefit from equol supplementation [PMID:38749724]. Microbiological differences, particularly elevated levels of Eikenella corrodens in subgingival plaque, have been identified as a distinguishing factor between DG and plaque-induced gingivitis, providing additional diagnostic utility [PMID:28304209]. However, the diagnostic process can be prolonged, with patients experiencing significant delays in diagnosis due to factors like less severe symptoms and the presence of other oral mucosal lesions or extraoral manifestations [PMID:32651518]. Robust methodologies, such as double-blind, crossover trials evaluating treatments like clobetasol propionate, are essential for refining diagnostic criteria and treatment efficacy [PMID:19784470].
Differential Diagnosis
Differentiating desquamative gingivitis (DG) from other conditions is crucial for appropriate management. Common differential diagnoses include chemical and electrical burns, allergic reactions, hormonal disorders (such as hypothyroidism), mucocutaneous diseases (e.g., lichen planus, pemphigus vulgaris, and mucous membrane pemphigoid), and reactions to oral hygiene products, medications, and dietary substances like cinnamon [PMID:5-7]. Conditions such as oral lichen planus (OLP), mucous membrane pemphigoid (MMP), and pemphigus vulgaris often present with overlapping symptoms, making clinical differentiation challenging. The presence of other oral mucosal lesions or extraoral manifestations can aid in quicker identification, as these factors are negatively correlated with diagnostic delays [PMID:32651518]. Notably, the effectiveness of treatments like fusidic acid suggests its potential role in distinguishing DG from other gingival conditions, given its significant impact on symptom reduction and lesion size [PMID:26312984].
Management
The management of desquamative gingivitis (DG) primarily revolves around pharmacological interventions tailored to modulate inflammation and promote mucosal healing. Topical corticosteroids, such as clobetasol propionate and tacrolimus, and immune modulators like cyclosporine, are commonly prescribed due to their efficacy in controlling symptoms and reducing inflammation [PMID:12-15]. While a double-blind, crossover trial with clobetasol propionate did not show statistically significant differences compared to placebo in clinical improvement [PMID:19784470], other studies highlight the variability in patient responses, necessitating individualized treatment plans. Emerging evidence suggests that equol supplementation may offer promising benefits, particularly in women, with a 12-month study demonstrating significant improvements in bleeding on probing, visual findings, and reductions in gingival pain [PMID:38749724]. Additionally, innovative approaches such as mucoadhesive patches containing hydrocortisone sodium succinate, enhanced with chitosan, gelatin, and keratin, show potential for localized treatment, offering controlled drug release and improved mechanical properties [PMID:28832260]. Managing subgingival colonization, particularly targeting Eikenella corrodens, is also crucial for effective control of DG [PMID:28304209]. Treatment with topical fusidic acid has shown substantial reductions in pain intensity and lesion size, with sustained benefits over 12 months, underscoring its role in symptom management [PMID:26312984]. Overall, a comprehensive approach that includes patient education, early diagnosis, and tailored pharmacological interventions is essential for optimal outcomes in DG management.
Prognosis & Follow-up
The prognosis of desquamative gingivitis (DG) varies among patients but generally improves with appropriate management. Long-term follow-up studies indicate sustained clinical improvements in patients receiving targeted treatments such as equol supplementation, with significant reductions in gingival pain and lesion size maintained over 12 months [PMID:38749724]. Similarly, patients treated with fusidic acid have reported sustained benefits in pain reduction and lesion size for up to 12 months post-treatment, highlighting the potential for long-term relief [PMID:26312984]. Regular follow-up appointments are crucial to monitor disease progression, adjust treatments as necessary, and address any emerging complications. Clinicians should emphasize the importance of consistent adherence to prescribed therapies and lifestyle modifications to optimize outcomes and minimize recurrence. Early intervention and ongoing patient education play pivotal roles in achieving favorable long-term prognoses for individuals with DG.
Key Recommendations
References
1 Kawamoto A, Sugano N, Sakai M, Ogisawa S, Shiratsuchi H, Seki K et al.. Clinical effect of equol supplementation in the treatment of desquamative gingivitis with 1-year follow-up. Journal of oral science 2024. link 2 Shaqman M, Hamdan A, Karadsheh O, Sawair F, Hassona Y. Desquamative gingivitis: a challenging diagnosis for clinicians. British dental journal 2020. link 3 Davoudi Z, Rabiee M, Houshmand B, Eslahi N, Khoshroo K, Rasoulianboroujeni M et al.. Development of chitosan/gelatin/keratin composite containing hydrocortisone sodium succinate as a buccal mucoadhesive patch to treat desquamative gingivitis. Drug development and industrial pharmacy 2018. link 4 Arduino PG, Romano F, Sasia D, Broccoletti R, Ricceri F, Barbui AM et al.. Subgingival Microbiota in White Patients With Desquamative Gingivitis: A Cross-Sectional Study. Journal of periodontology 2017. link 5 Leite FR, Nascimento GG, Demarco FF, Waechter J, Etges A. Use of Fusidic Acid for Desquamative Gingivitis Treatment: 1-Year Follow-Up. Brazilian dental journal 2015. link 6 Motta AC, Domaneschi C, Komesu MC, Souza Cda S, Aoki V, Migliari DA. Double-blind, crossover, placebo-controlled clinical trial with clobetasol propionate in desquamative gingivitis. Brazilian dental journal 2009. link
6 papers cited of 7 indexed.